AskBio receives FDA Fast Track and MHRA Innovation Passport Designations for AB-1005 Investigational GDNF Gene Therapy for Parkinson’s Disease

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track Designation for AB-1005, which is being developed for moderate Parkinson’s disease.